
Experts agree that developing value-based care models for atrial fibrillation requires collaborative, data-driven strategies—leveraging clinical pharmacists for personalized medication management and prioritizing stroke prevention and rhythm control—while embracing innovation and workforce redesign to balance quality, cost-effectiveness, and avoid overdiagnosis in an evolving health care landscape.